FTC clears Ortho-McNeil, Diamyd $45M diabetes deal

Justine Varieur Cadet | | Health Imaging | Enterprise Imaging
Diamyd Medical, a Stockholm-based diabetes developer of pharmaceuticals for the treatment of autoimmune diabetes and its complications, has received antitrust clearance that closes the transaction announced on June 22 with Ortho-McNeil-Janssen Pharmaceuticals, a Johnson & Johnson company.

The U.S. Federal Trade Commission’s clearance under the Hart-Scott-Rodino Anti-Trust Improvements Act is regarding the agreement between Diamyd and Ortho-McNeil for development and global commercialization of the GAD65 antigen-based therapy for the treatment and prevention of type 1 diabetes and associated conditions.

At the time of acquisition, Ortho-McNeil will pay Diamyd $45 million upfront and could receive milestone payments up to $580 million and future sales royalties.

Justine Varieur Cadet

Related Content

Less than half of incidental interstitial lung abnormalities on CT exams are reported
Are providers too trusting of AI's advice?
Pairing an alert system with CAD software halves time-to-treatment for pneumothorax
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Rads are more accurate when they have access to patients' self-reported symptoms
AI-based software improves follow-up imaging adherence by 74%

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.